Stockscreener 앱 받기
10.09
2.70%
-0.28
시간 외 거래:
10.09
Design Therapeutics Inc 주식(DSGN)의 최신 뉴스
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Earnings Risk: Will Design Therapeutics Inc benefit from green energy policies2025 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - Defense World
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
DSGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - Barchart.com
Stock List: Research Stocks from Around the World - GuruFocus
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - MarketBeat
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts - TradingView
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year HighWhat's Next? - MarketBeat
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED - PR Newswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - The Manila Times
K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026 - PR Newswire
DSGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials - Business Wire
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00 - Defense World
Ideas Watch: Can Design Therapeutics Inc expand its profit margins2025 Trading Recap & Capital Protection Trade Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
RSI Check: Is Trinseo PLC a potential multi baggerBond Market & Breakout Confirmation Alerts - baoquankhu1.vn
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
Biotech Design Therapeutics to brief investors at two healthcare events - Stock Titan
Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 14.0% - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Design Therapeutics Inc. stock recover after earningsJuly 2025 Sentiment & Fast Exit and Entry Trade Guides - mfd.ru
Design Therapeutics (NASDAQ:DSGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Is Design Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Earnings & Verified Chart Pattern Signals - mfd.ru
Trading Action: What is the long term forecast for Design Therapeutics Inc stockDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Retail Surge: Is Design Therapeutics Inc attractive for institutional investorsJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery - Business Wire
Design Therapeutics Approaches Key Clinical Milestones with Ample Funding - AD HOC NEWS
Published on: 2026-02-07 15:17:14 - baoquankhu1.vn
Is Design Therapeutics Inc. stock near bottom after decline2025 Market WrapUp & AI Powered Buy/Sell Recommendations - mfd.ru
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why - Defense World
Published on: 2026-02-01 06:18:16 - baoquankhu1.vn
Design Therapeutics announces governance-driven board resignation - The Globe and Mail
How volatile is Design Therapeutics Inc. stock2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Loss Report: How volatile is Design Therapeutics Inc stockEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
Design Therapeutics, Inc. Announces Resignation of Deepa Prasad from the Company's Board of Directors, Effective February 1, 2026 - marketscreener.com
Design Therapeutics (NASDAQ:DSGN) Shares Gap UpStill a Buy? - MarketBeat
Recap Report: Does Design Therapeutics Inc meet Warren Buffetts criteria2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Insider Sell: Can Design Therapeutics Inc expand its profit marginsBond Market & AI Enhanced Trading Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Bear Alert: Is Design Therapeutics Inc attractive for institutional investorsTrade Performance Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics - BioSpace
Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Business Wire
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Yahoo Finance
Design Therapeutics (NASDAQ:DSGN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Trading Recap: Will Bullfrog AI Holdings Inc Equity Warrant stock recover after earningsQuarterly Profit Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighHere's What Happened - MarketBeat
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad - The AI Journal
3.69%
0.68%
자본화:
|
볼륨(24시간):